Cencora reported fiscal third quarter revenue of $84.8 billion, a 5.1 percent year-over-year increase, with diluted earnings per share rising to $3.94 and adjusted diluted EPS reaching $4.48. The company raised its full-year adjusted diluted EPS guidance range to $17.75–$17.95 from the previous $17.70–$17.90. Additionally, Cencora repurchased $1 billion of shares during the quarter and declared a quarterly cash dividend of $0.60 per share payable on August 31, 2026, to record holders as of August 14, 2026. The company operates in the pharmaceutical distribution and healthcare solutions industry.
